Show simple item record

dc.contributor.authorDemir, I.
dc.contributor.authorSerin, I.
dc.contributor.authorPehlivan, S.
dc.contributor.authorPehlivan, M.
dc.contributor.authorOyaci, Y.
dc.date.accessioned2023-10-10T10:17:22Z
dc.date.available2023-10-10T10:17:22Z
dc.date.issued2022
dc.identifier.citationSerin I., Pehlivan S., Demir I., Oyaci Y., Pehlivan M., "A New Clock is Running for Multiple Myeloma: Circadian Clock Protein-Period 3 (PER-3) Polymorphism", BALKAN JOURNAL OF MEDICAL GENETICS, cilt.25, sa.2, ss.37-43, 2022
dc.identifier.issn1311-0160
dc.identifier.othervv_1032021
dc.identifier.otherav_0111bcd8-dfb9-4b39-89bc-62fb9e31619d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189156
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/0111bcd8-dfb9-4b39-89bc-62fb9e31619d/file
dc.identifier.urihttps://doi.org/10.2478/bjmg-2022-0026
dc.description.abstractCircadian Clock Protein PERIOD 3 (PER-3) is situated on chromosome 1p36.23 and has a polymorphic domain that expresses 4 or 5 copies of the 54-bp tandem repeat sequence. PER-3 gene polymorphisms play a role in the dysregulation of the immune system. This study intended to investigate the distributions and clinical effectiveness of the PER-3 gene polymorphism in multiple myeloma (MM) patients. One hundred fifty patients diagnosed between January 2007-2009 and 100 healthy individuals were included in this study. All patients were suitable for autologous stem cell transplantation (ASCT) at first evaluation, and after 4 courses of VCD at least partial remission, ASCT was carried out. Later, LD was used as maintenance. Genotypes of PER-3 gene of patients and healthy controls were statistically compared before treatment. In addition, these genotypes' effects on overall and progression free survival (OS and PFS) were investigated. Median PFS in the 5R/5R genotype was found to be significantly longer, albeit low, at 86% (p = 0.046). In the statistical analysis performed between the 4R/4R genotype and others, the PFS of patients with 4R/4R was found to be significantly shorter at 40.4 months (p = 0.026). Patients with the 4R/4R genotype would have a risk of 2.049 times of a shorter PFS (p=0.009). With this first study investigating the effect of a circadian gene in MM, the net effect of PER-3 gene polymorphism on PFS was revealed, and it will be a guide for future studies.
dc.language.isoeng
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectGENETİK VE KALITIM
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectGenetik (klinik)
dc.subjectMoleküler Biyoloji
dc.subjectGenetik
dc.titleA New Clock is Running for Multiple Myeloma: Circadian Clock Protein-Period 3 (PER-3) Polymorphism
dc.typeMakale
dc.relation.journalBALKAN JOURNAL OF MEDICAL GENETICS
dc.contributor.departmentUniv Hlth Sci , ,
dc.identifier.volume25
dc.identifier.issue2
dc.identifier.startpage37
dc.identifier.endpage43
dc.contributor.firstauthorID4315661


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record